Sigma Receptors as a Pharmacological Target for
Neuroprotectors. New Horizons of Pharmacotherapy of
Parkinson Disease

D. A. Abaimov^a and G. I. Kovalev^b,1

^aScientific Center of Neurology, Russian Academy of Medical Sciences, Moscow, Russia

^bZakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia

Received August 31, 2010

Abstract—In this review, we analyzed the possibility of using ligands of sigma receptors in the pharmacother-
apy of Parkinson disease. We reviewed the involvement of system of sigma receptors in the etiology and patho-
genesis of parkinsonism. We evaluated the role of sigma receptors in the regulation of the dopaminergic and
glutamatergic systems of the brain in the norm and during pathology. The contribution of sigma-coupled effects
to the general pharmacological profile of adamantane derivatives is discussed.

Keywords: sigma receptors, glutamate NMDA receptors, dopamine transporter, adamantane derivatives, par-
kinsonism

DOI: 10.1134/S1819712411010028

Pleiades Publishing home page | journal home page | top

If you have any problems with this server, contact webmaster.